Children's Hospital of Philadelphia Initiative Substantially Increases Naloxone Co-Prescribing when Outpatient Opioids Are Prescribed

Children’s Hospital of Philadelphia (CHOP) used an EHR-based automated alert plus provider/pharmacist and patient-family education to raise naloxone co-prescribing with outpatient opioid prescriptions from <3% in 2023 to an average monthly rate of 84.1% (goal: ≥80%) across the enterprise. The initiative improved naloxone dispensing despite ongoing barriers like stigma and medication costs, with nearly 60% of prescriptions filled through CHOP pharmacies. Results, published in The Journal of Pediatrics, position the framework as scalable for pediatric opioid safety practices to reduce preventable overdose harm.

Analysis

This is best read as a workflow signal, not a demand signal. The economic value is in turning a clinician behavior change into a default EHR action; that kind of standardization can scale quickly across health systems, but it does not automatically translate into material drug revenue because the unit economics of naloxone are tiny and highly price-sensitive.

The main beneficiaries are the channels that control dispense friction: integrated hospital pharmacies, community pharmacy networks, and whichever branded/OTC supply chain can secure coverage or discount-program eligibility. The second-order risk for smaller pharmacies is not lost volume but margin compression if co-prescribing becomes mandatory while reimbursement stays unchanged; the tradeable impact is therefore likely larger for operating metrics than for top-line growth.

Consensus may be overestimating how quickly this can move from a single pediatric system to a broad market. The real catalyst path is 1-3 quarters of state-level guidance updates, payer policy changes, and EMR template adoption; without those, this remains a best-practice case study. Falsifiers are simple: if fill rates stall because of out-of-pocket cost or stigma, the thesis shifts from "scalable adoption" to "administrative compliance," which is much less investable.

Key Decisions for Investors

• No position in PLCE; treat as non-actionable noise with no identifiable read-through over the next 1-3 months.
• Put EBS on a 3-6 month watchlist rather than trading it now; only consider a small long if broader state/payer adoption data confirms that co-prescribing is driving incremental dispensations, not just prescriptions.
• If expressing a channel-access view, prefer a modest CVS over WBA pair over 6-12 months; CVS has better script-to-dispense capture potential, while WBA has more operational fragility if low-dollar safety scripts expand without reimbursement support.
• Set an alert on naloxone fill-rate data and pharmacy abandonment rates; if out-of-pocket costs remain the binding constraint, avoid any long thesis in EBS or pharmacy proxies.